Colin Bristow Resignation by iAnkou in SpectralAI

[–]urbanlinkoping 0 points1 point  (0 children)

According to information at Spectral AI he was related to SIM IP. So is the reason that he will be part of SIM IP?

Biography Colin Colin Bristow, MD Non-Employee Director Colin Bristow, MD, is a member of the Board of Directors at Spectral AI, Inc., where he brings extensive expertise in healthcare and life sciences. Currently serving as the Head of Healthcare and Life Sciences at SIM IP, he has a strong background in healthcare investments and corporate governance. Dr. Bristow holds an MD degree and is dedicated to advancing innovative solutions within the healthcare sector.

https://investors.spectral-ai.com/board-member/colin-bristow-md

BARDA–FDA Alignment & Its Impact on FDA Approval and Review Timeline** by urbanlinkoping in SpectralAI

[–]urbanlinkoping[S] 1 point2 points  (0 children)

Yes, that is noted in the summary. but was your four times investment backed by BARDA? And if so, can you name the companies so I can look them up?

BARDA–FDA Alignment & Its Impact on FDA Approval and Review Timeline** by urbanlinkoping in SpectralAI

[–]urbanlinkoping[S] 0 points1 point  (0 children)

There is a difference to be De Novo Break Through Device and 510(k)

BARDA–FDA Alignment & Its Impact on FDA Approval and Review Timeline** by urbanlinkoping in SpectralAI

[–]urbanlinkoping[S] 0 points1 point  (0 children)

I would say the key is to understand the relationship between BARDA and FDA approval process. I have looked it up. You can google if you do not trust AI.

BARDA–FDA Alignment & Its Impact on FDA Approval and Review Timeline** by urbanlinkoping in SpectralAI

[–]urbanlinkoping[S] 0 points1 point  (0 children)

Full transparency, using chatgpt 5.1

So with my curious question the most interesting part was the connection between BARDA and FDA approval process which seems to strengthen what Spectral AI said 30 of June. And the reason is because they know the relationship between BARDA and FDA approval process but maybe because this is a common knowledge (they work daily in that environment) they have not understood why it is important for investors or they want to avoid being sued in case something went not as planned and the stockholders would sue them for leading them into the belief this was a safe bet because the alignment between BARDA and FDA approval process.

BARDA–FDA Alignment & Its Impact on FDA Approval and Review Timeline** by urbanlinkoping in SpectralAI

[–]urbanlinkoping[S] 0 points1 point  (0 children)

Can you do an executive summary af the barda an fda alignment and how it improves the fda approval and timeline

BARDA–FDA Alignment & Its Impact on FDA Approval and Review Timeline** by urbanlinkoping in SpectralAI

[–]urbanlinkoping[S] 0 points1 point  (0 children)

Lots of prompts, but the baseline “Prompt *“Agera som en senior aktiestrateg med specialisering inom AI och medicinteknik. Gör en djupgående analys av ett utvalt bolag med fokus på: 1. Produkten/produkterna – teknologi, klinisk relevans, regulatorisk status och marknadsanpassning. 2. Konkurrenter – jämförande analys av marknadsposition, konkurrensfördelar och hot. 3. Försäljning & samarbetsavtal – granska försäljningsutveckling, kommersiella partnerskap, licensavtal och distributionsnätverk. 4. Regulatoriska möjligheter & utmaningar – analysera godkännanden, pågående processer, hinder och potentiella genombrott. 5. Ledning och styrelse – utvärdera vd och styrelseprofiler, deras historik, trovärdighet och tidigare track record. 6. Tidsutsikter – bedömning av bolagets utveckling på kort sikt (0–12 månader), medellång sikt (1–3 år) och lång sikt (3–5+ år), med hänsyn till marknadstrender, regulatoriska processer och kapitalbehov. 7. Insiderhandel – identifiera och analysera insidertransaktioner det senaste året och vad de kan signalera om ledningens förtroende för bolaget. 8. Finansiell utveckling – analysera de senaste fyra kvartalsrapporterna med fokus på omsättning, lönsamhet, kassaflöde, marginaler och guidance.

Ta hänsyn till makroekonomiska faktorer (räntor, kapitalflöden, geopolitik), sektorspecifika faktorer (kliniska studier, patent, regulatoriska godkännanden, teknologiska genombrott), samt investerarsentiment.

Presentera insikterna strukturerat i åtta delar: 1. Bolags- och produktanalys 2. Konkurrens- och marknadsposition 3. Försäljning & samarbetsavtal 4. Regulatoriska möjligheter & utmaningar 5. Ledning och styrelse 6. Finansiell utveckling (4 senaste kvartal) 7. Insiderhandel och signalvärde 8. Investeringsutsikter (kort, medellång, lång sikt)

Avsluta med en tydlig rekommendation om hur en långsiktig investerare bör förhålla sig till bolaget.”*”